Natco Pharma Q2 Profit up 35 percent to Rs 583 Crore
Hyderabad: Natco Pharma Limited has recorded consolidated total revenue of INR 583.50 Crore for the second quarter ended on 30th September 2018, as against INR 432.20 Crore for the same period last year, reflecting a growth of 35%.
The net profit for the period, on a consolidated basis, was INR 181.60 Crores as against INR 84.40 Crore same period last year, showing a growth of 115%.
During the quarter, the company has witnessed growth in the formulations business- both domestic and exports. The breakup of revenues has Formulations domestic Rs. 193.87 crores, Formulation exports including profit share/service income Rs. 247.81 crores, APIrevenues Rs. 66.81 crores, other operating / other income Rs.53.61 crores and subsidiary revenues Rs. 21.40 crores for quarter ended 30th September 2018.
The net profit for the period, on a consolidated basis, was INR 181.60 Crores as against INR 84.40 Crore same period last year, showing a growth of 115%.
During the quarter, the company has witnessed growth in the formulations business- both domestic and exports. The breakup of revenues has Formulations domestic Rs. 193.87 crores, Formulation exports including profit share/service income Rs. 247.81 crores, APIrevenues Rs. 66.81 crores, other operating / other income Rs.53.61 crores and subsidiary revenues Rs. 21.40 crores for quarter ended 30th September 2018.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd